Ian W. Flinn, MD, PhD, Sarah Cannon Research Institute

Articles

Diffuse Large B-Cell Lymphoma: Unmet Needs and Future Directions in Care

August 7th 2023

Closing out their discussion on the management of relapsed/refractory diffuse large B-cell lymphoma, expert panelists highlight unmet needs and share excitement for future evolutions in the treatment landscape.

Management of Diffuse Large B-Cell Lymphoma: Data From ASCO 2023

July 31st 2023

Key opinion leaders reflect on data from the 2023 ASCO meeting and how it may impact the management of diffuse large B-cell lymphoma.

Diffuse Large B-Cell Lymphoma: Moving Novel Therapy to the Frontline Setting

July 31st 2023

Expert perspectives on recent efforts to move novel therapy from the relapsed/refractory to frontline setting of diffuse large B-cell lymphoma.

Bridging Therapy in Relapsed/Refractory Diffuse Large B-Cell Lymphoma

July 24th 2023

Before closing out their discussion on the relapsed/refractory setting of diffuse large B-cell lymphoma, panelists identify best practices in bridging therapy.

Sequencing Novel Therapies in Relapsed/Refractory Diffuse Large B-Cell Lymphoma

July 24th 2023

Comprehensive insight on the optimal sequencing of novel therapies in patients with relapsed/refractory diffuse large B-cell lymphoma.

What is the Role of Bispecifics in Relapsed/Refractory DLBCL?

July 17th 2023

Shared insight from key opinion leaders in diffuse large B-cell lymphoma on the role of bispecific therapy in the relapsed/refractory space.

Relapsed/Refractory DLBCL: Managing Patients on CAR T-Cell Therapy

July 17th 2023

A brief review of what one can expect while managing a patient with relapsed/refractory diffuse large B-cell lymphoma on CAR T-cell therapy.

Factors That Inform Sequencing of Therapy in Relapsed/Refractory DLBCL

July 10th 2023

Moving into their last module, expert panelists consider how they might inform best selection and sequencing of therapy in patients with relapsed/refractory diffuse large B-cell lymphoma.

Real-World Use of CAR T-Cell Therapy in Relapsed/Refractory DLBCL

July 10th 2023

Following their discussion on axicabtagene ciloleucel and lisocabtagene maraleucel, panelists reflect on the real-world use of CAR T-cell therapy in relapsed/refractory diffuse large B-cell lymphoma.

CAR T-Cell Therapy in Relapsed/Refractory DLBCL: Lisocabtagene Maraleucel

July 3rd 2023

A brief review of data behind lisocabtagene maraleucel and its role as CAR T-cell therapy in patients with relapsed/refractory diffuse large B-cell lymphoma.

CAR T-Cell Therapy in Relapsed/Refractory DLBCL: Axicabtagene Ciloleucel

July 3rd 2023

Shared insight on the role of CAR T-cell therapy in relapsed/refractory diffuse large B-cell lymphoma, with a focus on axicabtagene ciloleucel.

Tafasitamab + Lenalidomide Therapy in Relapsed/Refractory DLBCL

June 26th 2023

Panelists review data behind the combination of tafasitamab and lenalidomide in relapsed/refractory diffuse large B-cell lymphoma.

Factors in Selecting Treatment for Relapsed/Refractory DLBCL

June 26th 2023

Focused discussion on specific patient or disease factors that aid in the selection of therapy for patients with relapsed/refractory diffuse large B-cell lymphoma.

Overview of Relapsed/Refractory DLBCL and Management Strategies

June 19th 2023

Key opinion leaders share a broad perspective on relapsed/refractory diffuse large B-cell lymphoma and the current treatment landscape.

Diagnosis and Frontline Management of Diffuse Large B-Cell Lymphoma

June 19th 2023

Expert panelists open their discussion on diffuse large B-cell lymphoma by reflecting on diagnostic strategies and the frontline treatment armamentarium.